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Little is known regarding optimal tacrolimus (TAC) trough levels after 1 year post-transplant
in stable kidney transplant recipients (KTRs) who have not experienced renal or cardiovas-
cular outcomes. This study aimed to investigate the effect of 1-year post-transplant TAC
trough levels on long-term renal and cardiovascular outcomes and opportunistic infections
in stable KTRs.
Methods
KTRs receiving TAC with mycophenolate-based immunosuppression who did not experi-
ence renal or cardiovascular outcomes within 1 year post-transplant were enrolled from a
multicenter observational cohort study. Renal outcome was defined as a composite of
biopsy-proven acute rejection, interstitial fibrosis and tubular atrophy, and death-censored
graft loss. Cardiovascular outcome was defined as a composite of de novo cardiomegaly,
left ventricular hypertrophy, and cardiovascular events. Opportunistic infections were
defined as the occurrence of BK virus or cytomegalovirus infections.
Results
A total of 603 eligible KTRs were divided into the low-level TAC (LL-TAC) and high-level
TAC (HL-TAC) groups based on a median TAC level of 5.9 ng/mL (range 1.3–14.3) at 1
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year post-transplant. The HL-TAC group had significantly higher TAC trough levels at 2, 3,
4, and 5 years compared with the levels of the LL-TAC group. During the mean follow-up of
63.7 ± 13.0 months, there were 121 renal outcomes and 224 cardiovascular outcomes. In
multivariate Cox regression analysis, LL-TAC and HL-TAC were not independent risk fac-
tors for renal and cardiovascular outcomes, respectively. No significant differences in the
development of opportunistic infections and de novo donor-specific anti-human leukocyte
antigen antibodies and renal allograft function were observed between the two groups.
Conclusions
TAC trough levels after 1 year post-transplant remained at a similar level until the fifth year
after kidney transplantation and were not directly associated with long-term outcomes in sta-
ble Korean KTRs who did not experience renal or cardiovascular outcomes. Therefore, in
Asian KTRs with a stable clinical course, TAC trough levels higher than approximately 6 ng/
mL might not be required after a year of kidney transplantation.
Introduction
Underdosing of tacrolimus (TAC) in kidney transplant recipients (KTRs) can lead to biopsy-
proven acute rejection (BPAR) and immunologic sensitization; however, overdosing of TAC
can result in calcineurin inhibitor (CNI) toxicity and opportunistic infections including BK
virus and cytomegalovirus (CMV) infections, which have detrimental effects on renal allograft
outcomes [1–5]. Furthermore, CNI exposure can increase the risk of new-onset diabetes melli-
tus, hypertension, and lipid dysregulation, which are considered as potential risk factors for
cardiovascular disease [6]. Therefore, the maintenance of optimal TAC trough levels is crucial
to improve transplant outcomes.
Optimal TAC trough levels may be different according to the post-transplant period. Previ-
ous studies have reported an association between TAC trough levels within 1 year post-trans-
plant and kidney transplantation outcomes [7–20]. The Kidney Disease: Improving Global
Outcomes guidelines suggest that 5–15 ng/mL of TAC trough levels should be maintained dur-
ing the first 2–4 months post-transplant and then reduced in stable KTRs to minimize toxicity,
with a low quality of evidence [21]. However, little is known regarding optimal TAC trough
levels after 1 year post-transplant in stable KTRs who have not experienced renal or cardiovas-
cular outcomes. Furthermore, since ethnicity can affect tacrolimus pharmacokinetics [22], it is
crucial to determine the optimal TAC trough levels in Asian KTRs.
This study aimed to investigate the effect of 1-year post-transplant TAC trough levels on
renal and cardiovascular outcomes in stable Korean KTRs who did not experience renal or car-
diovascular outcomes within 1 year post-transplant.
Materials and methods
Participants
De novo KTRs were enrolled from the Korean Cohort Study for Outcome in Patients with Kid-
ney Transplantation (KNOW-KT) between 2012 and 2016 and followed up until 2019. Out of
1,080 KTRs, we included 707 KTRs receiving TAC with mycophenolate-based immunosup-
pression at 1 year. Overall, 101 KTRs who experienced renal or cardiovascular outcomes
within 1 year post-transplant (renal = 94, cardiovascular = 33, both = 26), 1 patient with TAC
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trough levels > 20 ng/mL, and 2 patients with insufficient information were excluded. As a
result, 603 KTRs were included in this study. The Institutional Review Committee of each par-
ticipating center approved the KNOW-KT study protocol [Chonbuk National University Hos-
pital; Gachon University Gil Medical Center; Keimyung University Dongsan Hospital; Korea
University Anam Hospital; Kyungpook National University Hospital; Samsung Medical Cen-
ter, Seoul; Seoul National University Hospital; Yonsei University, Severance Hospital (in
alphabetical order)] [23]. All patients provided their written informed consent before partici-
pating in the study. All clinical investigations were conducted in accordance with the guide-
lines of the 2008 Declaration of Helsinki.
Variables
TAC trough levels and TAC dosages were recorded at 1 year and annually thereafter. TAC
trough levels and TAC dosages were determined by the physicians’ clinical judgment. Eligible
KTRs were divided into the low-level TAC (LL-TAC) and high-level TAC (HL-TAC) groups
based on a median TAC level of 5.9 ng/mL (range 1.3–14.3) at 1 year post-transplant.
Possible confounders for renal composite endpoints included TAC trough level, TAC dos-
age, age, sex, body mass index (BMI), number of human leukocyte antigen (HLA) mismatches,
type of transplant donor, re-transplantation, and desensitization. Possible confounders for car-
diovascular composite endpoints included TAC trough levels, TAC dosage, age, sex, BMI, pri-
mary kidney disease, dialysis duration, smoking, total cholesterol, high-density lipoprotein
(HDL), and systolic blood pressure (BP).
Information on de novo donor-specific anti-HLA antibodies (DSAs) was obtained at base-
line, 1 year, and 5 years post-transplant and when clinically indicated.
Outcomes
Renal outcome was defined as a composite of BPAR, interstitial fibrosis and tubular atrophy
(IFTA), and death-censored graft loss after 1 year post-transplant. IFTA grade I, II, and III
were included. Cardiovascular outcome was defined as a composite of de novo cardiomegaly
on chest X-ray, left ventricular hypertrophy on electrocardiogram, and cardiovascular events
after 1 year post-transplant. Chest X-ray and electrocardiogram were performed at baseline
and annual visits. Cardiomegaly on chest X-ray was defined as cardiothoracic ratio > 50%.
Cardiovascular events were defined as myocardial infarction, unstable angina, percutaneous
coronary intervention, coronary artery bypass grafting, or stroke. The development of de novo
DSAs and estimated glomerular filtration rates (eGFRs) were compared between the two
groups.
Opportunistic infections were defined as the occurrence of BK virus or CMV infections.
BK virus infection was defined as an occurrence of BK viremia (� 104 copies/mL) or diag-
nosed biopsy-proven BK virus nephropathy. CMV infection was defined as a presence of sig-
nificant positive CMV polymerase chain reaction or diagnosed CMV disease.
Statistical analysis
Continuous variables are expressed as the mean ± standard deviation for normally distributed
data and as the median with range when the values were not normally distributed. Differences
between the groups were assessed by independent sample t-tests and chi-squared tests as
appropriate. The Cox regression model was used to analyze the factors associated with the
development of renal and cardiovascular outcomes and opportunistic infections. The cumula-
tive incidences of renal and cardiovascular outcomes were analyzed according to TAC trough
levels using the Kaplan-Meier method. Statistical analysis was performed using the SAS system
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Table 1 shows the baseline characteristics according to a median TAC level of 5.9 ng/mL at 1
year post-transplant. The mean TAC trough levels were 7.8 ± 1.6 and 4.6 ± 1.0 ng/mL in KTRs
with HL-TAC and LL-TAC, respectively. In comparison with patients with HL-TAC, those
with LL-TAC were significantly younger (46.6 ± 11.2 vs. 44.7 ± 11.4 years, P = 0.041) and
received less anti-thymocyte globulin as induction therapy (14.7 vs. 6.6%, P = 0.001). There
were no significant differences in TAC dose, mycophenolic acid dose, the use of steroid, recipi-
ent sex, donor age, donor sex, BMI, primary kidney disease, dialysis duration, type of trans-
plant donor, re-transplantation, number of HLA mismatches, panel reactive antibody
positivity, desensitization, smoking, lipid profile, BP, the use of angiotensin-converting
enzyme inhibitors, angiotensin II receptor blockers, and statins, DSAs at 1 year, and eGFR at 1
year.
TAC trough levels and renal outcomes
Patients with HL-TAC at 1 year had significantly higher TAC trough levels at 2 years (6.4 ± 5.2
vs. 5.2 ± 1.8 ng/mL, P < 0.001), 3 years (6.0 ± 1.9 vs. 5.2 ± 1.8 ng/mL, P < 0.001), 4 years
(6.1 ± 2.1 vs. 5.1 ± 1.7 ng/mL, P < 0.001), and 5 years (5.9 ± 5.3 vs. 5.3 ± 2.1 ng/mL, P< 0.001)
compared with the levels of patients with LL-TAC (Fig 1).
During the mean follow-up of 63.7 ± 13.0 months, 121 renal outcomes occurred after 1
year post-transplant. Detailed information on renal outcomes is presented in S1 Table. Univar-
iate and multivariate Cox regression analysis demonstrated that TAC trough levels, TAC dose,
age, sex, BMI, number of HLA mismatches, re-transplantation, and desensitization were not
significantly associated with renal composite endpoints (Table 2).
Multivariate Cox regression analysis for BPRA or IFTA are shown in S2 Table. TAC trough
levels were not significantly associated with both BPRA and IFTA.
Kaplan-Meier analysis showed that there was no significant difference in the development
of renal outcomes between the HL-TAC and LL-TAC groups (Fig 2A).
TAC trough levels of 5.0–5.9,� 5, and� 4 ng/mL compared with> 5.9 ng/mL were not asso-
ciated with renal composite endpoints even after adjusting for TAC dose, age, sex, BMI, number
of HLA mismatches, type of transplant donor, re-transplantation, and desensitization (Table 3).
Subgroup analysis including deceased donor and deceased donor with donor age� 60 revealed
that renal outcome was not associated with LL-TAC compared with HL-TAC.
TAC trough levels and cardiovascular outcomes
A total of 224 cardiovascular outcomes were observed during the follow-up. Detailed informa-
tion on cardiovascular outcomes is presented in S1 Table. Univariate and multivariate Cox
regression analysis demonstrated that TAC trough levels, TAC dose, age, sex, BMI, primary
kidney disease, smoking, serum total cholesterol, HDL, and systolic BP were not significantly
associated with cardiovascular composite endpoints (Table 4). Multivariate Cox regression
analysis showed that dialysis duration was an independent predictor of the development of
cardiovascular outcomes (HR = 1.01, 95% CI 1.00–1.01, P < 0.001).
No significant difference in the development of cardiovascular outcomes between the
HL-TAC and LL-TAC groups was observed in the Kaplan-Meier plot (Fig 2B).
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Table 1. Baseline characteristics.
Variables TAC > 5.9 ng/mL (n = 299) TAC� 5.9 ng/mL (n = 304) P value
TAC trough levels at 1 year, ng/mL 7.8 ± 1.6 4.6 ± 1.0 < 0.001
TAC dose at 1 year, mg 3.9 ± 2.5 3.5 ± 1.9 0.065
MMF dose at 1 year, mg 942.5 ± 284.4 (n = 181) 935.4 ± 318.4 (n = 204) 0.819
EC-MPS dose at 1 year, mg 659.5 ± 247.2 (n = 118) 677.8 ± 220.0 (n = 100) 0.567
Use of steroid at 1 year, n (%)
Yes 270 (90.3) 273 (89.8) 0.838
Missing 29 (9.7) 31 (10.2)
Recipient age, years 46.6 ± 11.2 44.7 ± 11.4 0.041
Recipient sex, male, n (%) 194 (64.9) 184 (60.5) 0.269
Donor age, years 44.1 ± 11.9 43.8 ± 12.1 0.748
Donor sex, male, n (%) 159 (53.2) 151 (49. 7) 0.389
Recipient BMI, kg/m2 22.8 ± 3.5 22.7 ± 3.5 0.512
Primary kidney disease, n (%)
Diabetes 65 (21.7) 65 (21.4) 0.819
Non-diabetes 196 (65.6) 195 (64.1)
Unknown 38 (12.7) 44 (14.5)
Dialysis duration, months 25.1 ± 40.8 27.4 ± 46.3 0.523
Type of donor, n (%)
Living 246 (82.3) 241 (79.3) 0.350
Deceased 53 (17.7) 63 (20.7)
Re-transplantation, n (%) 21 (7.0) 19 (6.3) 0.703
Number of HLA mismatches
Total 3.4 ± 1.6 3.3 ± 1.6 0.706
DR 1.1 ± 0.7 1.1 ± 0.7 0.513
PRA positivity (> 0%), n (%) 93 (31.1) 111 (36.6) 0.152
Desensitization, n (%) 85 (28.6) 66 (21.8) 0.054
Induction therapy, n (%)
IL-2RB 255 (85.3) 284 (93.4) 0.001
ATG 44 (14.7) 20 (6.6)
Smoking at KT
Never 147 (49.2) 168 (55.3) 0.295
Current or former 150 (50.2) 134 (44.1)
Missing 2 (0.7) 2 (0.7)
Total cholesterol at 1 year, mg/dL 177.1 ± 34.68 177.7 ± 34.7 0.818
LDL at 1 year, mg/dL 98.2 ± 28.0 98.5 ± 28.6 0.922
HDL at 1 year, mg/dL 56.3 ± 17.1 59.1 ± 17.7 0.052
SBP at 1 year, mmHg 124.7 ± 11.9 123.5 ± 13.0 0.244
DBP at 1 year, mmHg 78.4 ± 10.4 77.7 ± 10.5 0.425
Use of drugs at 1 year, n (%)
ACE inhibitors/ARBs 42 (14.1) 34 (11.2) 0.300
Statins 132 (44.2) 141 (46.5) 0.556
DSAs at 1 year, n (%) 13 (4.3) 17 (5.6) 0.067
Values are shown as the mean ± standard deviation (range) or number (%).
Abbreviations: ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; ATG; anti-thymocyte globulin; BMI, body mass index; DBP, diastolic
blood pressure; DSA, donor-specific anti-human leukocyte antigen antibodies; EC-MPS, enteric-coated mycophenolate sodium; HDL, high-density lipoprotein; HLA,
human leukocyte antigen; IL-2RB, interleukin-2 receptor blocker; KT, kidney transplantation; LDL, low-density lipoprotein; MMF, mycophenolate mofetil; PRA, panel
reactive antibody; SBP, systolic blood pressure; TAC, tacrolimus.
https://doi.org/10.1371/journal.pone.0235418.t001
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TAC trough levels and opportunistic infections
During the follow-up, 5 BK virus infections and 60 CMV infections occurred after 1 year post-
transplant. Univariate and multivariate Cox regression analysis demonstrated that TAC trough
levels, age, sex, BMI, number of HLA mismatches, re-transplantation, and desensitization
were not significantly associated with opportunistic infections (Table 5). TAC dose was an
independent risk factor for the development of opportunistic infections.
TAC trough levels, de novo DSAs, and renal allograft function
No significant difference in the development of de novo DSAs between the HL-TAC and
LL-TAC groups was observed in the Kaplan-Meier plot (Fig 3).
There were no significant differences in eGFRs at 2 years (67.0 ± 18.1 vs. 65.5 ± 18.8 mL/
min/1.73 m2, P = 0.648), 3 years (67.8 ± 19.4 vs. 67.1 ± 20.2 mL/min/1.73 m2, P = 0.662), 4
Fig 1. TAC trough levels at 2, 3, 4, and 5 years post-transplant. Patients with HL-TAC at 1 year had significantly higher TAC trough levels at 2 years (6.4 ± 5.2 vs.
5.2 ± 1.8 ng/mL, P< 0.001), 3 years (6.0 ± 1.9 vs. 5.2 ± 1.8 ng/mL, P< 0.001), 4 years (6.1 ± 2.1 vs. 5.1 ± 1.7 ng/mL, P< 0.001), and 5 years (5.9 ± 5.3 vs. 5.3 ± 2.1 ng/mL,
P< 0.001) compared with the levels of patients with LL-TAC. �P< 0.001. Abbreviations: LL, low-level; HL, high-level; TAC, tacrolimus.
https://doi.org/10.1371/journal.pone.0235418.g001
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years (66.9 ± 21.4 vs. 65.2 ± 20.8 mL/min/1.73 m2, P = 0.417), and 5 years (68.3 ± 21.3 vs.
64.9 ± 24.4 mL/min/1.73 m2, P = 0.273) between the HL-TAC and LL-TAC groups (Fig 4).
Discussion
In this multicenter cohort study, TAC trough levels after 1 year post-transplant remained at a
similar level until the fifth year after kidney transplantation. No significant association was
Table 2. Univariate and multivariate Cox regression analysis for renal composite endpoints.
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
TAC� 5.9 vs. TAC > 5.9, ng/mL 0.83 (0.58–1.18) 0.298 0.85 (0.59–1.23) 0.389
TAC dose, mg 1.06 (0.99–1.13) 0.079 1.06 (0.99–1.13) 0.079
Age, years 1.00 (0.98–1.01) 0.525 0.99 (0.97–1.01) 0.373
Men vs. women 1.28 (0.87–1.87) 0.207 1.25 (0.84–1.85) 0.272
BMI, kg/m2 1.02 (0.97–1.07) 0.521 1.02 (0.97–1.08) 0.489
Number of HLA mismatches
Total 1.04 (0.93–1.17) 0.475 1.10 (0.90–1.33) 0.354
DR 1.02 (0.79–1.32) 0.889 0.87 (0.56–1.36) 0.534
Deceased vs. living donor 1.19 (0.77–1.82) 0.437 1.27 (0.80–2.01) 0.311
Re-transplantation 1.01 (0.49–2.06) 0.988 0.97 (0.47–2.02) 0.938
Desensitization 1.11 (0.74–1.67) 0.608 1.21 (0.79–1.86) 0.391
Abbreviations: BMI, body mass index; CI, confidence interval; HLA, human leukocyte antigen; HR, hazards ratio; TAC, tacrolimus.
https://doi.org/10.1371/journal.pone.0235418.t002
Fig 2. Cumulative incidence of (A) renal composite endpoints and (B) cardiovascular composite endpoints according to TAC trough levels. No significant differences in
the development of renal and cardiovascular outcomes between the HL-TAC and LL-TAC groups were observed in the Kaplan-Meier plot. Abbreviations: LL, low-level;
HL, high-level; TAC, tacrolimus.
https://doi.org/10.1371/journal.pone.0235418.g002
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found between 1-year post-transplant TAC trough levels and long-term renal and cardiovascu-
lar outcomes and opportunistic infections in stable Korean KTRs who did not experience
renal and cardiovascular outcomes within 1 year post-transplant. Furthermore, TAC trough
levels of> 5.9 ng/mL compared with� 5, 5.0–5.9, and� 5.9 ng/mL did not show any benefits
in terms of outcomes as well as the development of de novo DSAs and renal allograft function.
Subgroup analysis including deceased donor or deceased donor with donor age� 60 also
showed consistent results.
There are limited data on stable KTRs, especially in the Asian population, who have not
experienced any outcomes including rejection in the first year following kidney
Table 3. Univariate and multivariate Cox regression analysis for renal composite endpoints in subgroups.
Subdivided TAC trough levels HR (95% CI) P value
5.0 < TAC� 5.9 vs. TAC > 5.9, ng/mL Univariate 1.09 (0.67–1.76) 0.734
Multivariate� 1.13 (0.69–1.85) 0.617
TAC� 5 vs. TAC > 5.9, ng/mL Univariate 0.78 (0.51–1.18) 0.231
Multivariate� 0.74 (0.49–1.13) 0.166
TAC� 4 vs. TAC > 5.9, ng/mL Univariate 1.01 (0.60–1.70) 0.970
Multivariate� 1.01 (0.59–1.71) 0.986
Subgroups: TAC� 5.9 vs. TAC > 5.9, ng/mL
Deceased donor Univariate 0.75 (0.35–1.60) 0.458
Deceased donor & donor age � 60 years Univariate 0.62 (0.10–3.75) 0.606
Abbreviations: CI, confidence interval; HR, hazards ratio; TAC, tacrolimus.
�Adjusted for TAC dose, age, sex, BMI, number of HLA mismatches, type of transplant donor, re-transplantation, desensitization, and induction therapy.
https://doi.org/10.1371/journal.pone.0235418.t003
Table 4. Univariate and multivariate Cox regression analysis for cardiovascular composite endpoints.
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
TAC > 5.9 vs. TAC� 5.9, ng/mL 0.80 (0.62–1.04) 0.102 0.76 (0.58–1.01) 0.055
TAC dose, mg 0.99 (0.93–1.05) 0.642 0.99 (0.93–1.05) 0.658
Age, years 1.01 (1.00–1.02) 0.171 1.01 (0.99–1.02) 0.270
Men vs. women 1.46 (1.10–1.94) 0.010 1.31 (0.90–1.90) 0.161
BMI, kg/m2 1.02 (0.98–1.05) 0.420 0.98 (0.94–1.03) 0.475
Primary kidney disease
Diabetes 1.15 (0.83–1.59) 0.397 1.08 (0.76–1.53) 0.656
Non-diabetes Reference Reference
Unknown 1.35 (0.94–1.93) 0.107 1.61 (0.80–1.69) 0.437
Dialysis duration, months 1.01 (1.00–1.01) < 0.001 1.01 (1.00–1.01) < 0.001
Smoking at KT
Never Reference Reference
Current or former 1.28 (0.98–1.66) 0.071 1.07 (0.77–1.48) 0.694
Missing 2.34 (0.58–9.48) 0.235 1.79 (0.24–13.61) 0.573
Total cholesterol at 1 year, mg/dL 1.00 (1.00–1.01) 0.314 1.00 (1.00–1.01) 0.103
HDL at 1 year, mg/dL 1.00 (0.99–1.00) 0.360 1.00 (0.99–1.01) 0.530
SBP at 1 year, mmHg 1.01 (1.00–1.02) 0.086 1.01 (1.00–1.02) 0.119
Abbreviations: BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; HR, hazards ratio; KT, kidney transplantation; SBP, systolic blood
pressure; TAC, tacrolimus.
https://doi.org/10.1371/journal.pone.0235418.t004
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transplantation. In this study, TAC trough levels higher than approximately 6 ng/mL did not
exhibit any beneficial effect on reducing renal outcomes including the development of de novo
DSAs in stable KTRs. Although an existing large-scale study reported TAC trough levels > 5
ng/mL after 1 year post-transplant as optimal for preventing the development of de novo
DSAs, the study differed considerably from this study in that it included all patients who expe-
rienced BPAR within a year after kidney transplantation [19]. As BPAR itself can affect trans-
plant outcomes and the target range of TAC trough levels, this study excluded those with
clinical events within 1 year. Furthermore, TAC trough levels< 5 ng/mL in patients with low
HLA alloimmune response did not increase the risk of de novo DSA development, indicating
that not all KTRs may have a standard TAC trough level target of above 5 ng/mL [19]. There-
fore, the TAC trough level target should be adjusted based on previous BPAR history as well as
the individual’s alloimmune risk.
CNIs have been reported to cause dyslipidemia and vascular calcification dose-dependently,
and these conditions may increase cardiovascular outcomes [6]. However, the reduction of
cardiovascular outcomes by optimal TAC trough levels has not been investigated. Contrary to
our expectations, high TAC trough levels did not increase the risk of cardiovascular outcomes
in this study. Instead, pretransplant dialysis duration was an independent risk factor for car-
diovascular outcomes even after adjusting for Framingham risk factors. The result of the pres-
ent study is consistent with that of a previous study, which reported pretransplant dialysis
duration as an independent predictor of patient death resulting from cardiovascular diseases
[24]. The pathogenesis may be attributed to the rapid progression of cardiovascular changes
including vascular calcification and left ventricular hypertrophy [25], increased inflammation
[26], and changes in concentrations of advanced glycosylation end products [27].
This study has some limitations. First, this study was not a randomized controlled study but
an observational study. The results of our study are not completely unaffected by the physi-
cian’s strategies and clinical circumstances of KTRs. Second, as the TAC trough level involved
a single drug concentration, there may be a lack of representation. However, KTRs with
HL-TAC at 1 year post-transplant also had significantly higher TAC trough levels until 5 years
post-transplant. The sustained higher or lower TAC trough levels for the following 5 years
may be explained by individual genetic predispositions, as reported in previous studies about
the association between cytochromeP450(CYP)3A5 gene polymorphisms, the dose
Table 5. Univariate and multivariate Cox regression analysis for opportunistic infections.
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
TAC� 5.9 vs. TAC > 5.9, ng/mL 0.89 (0.54–1.44) 0.622 1.00 (0.60–1.64) 0.986
TAC dose, mg 1.11 (1.03–1.20) 0.009 1.11 (1.02–1.21) 0.013
Age, years 0.99 (0.97–1.02) 0.568 0.99 (0.97–1.02) 0.568
Men vs. women 1.09 (0.65–1.81) 0.746 1.19 (0.69–2.04) 0.529
BMI, kg/m2 0.99 (0.92–1.06) 0.683 0.98 (0.90–1.06) 0.534
Number of HLA mismatches
Total 1.17 (0.99–1.37) 0.059 1.17 (0.89–1.54) 0.252
DR 1.30 (0.90–1.86) 0.159 0.94 (0.50–1.75) 0.841
Deceased vs. living donor 0.75 (0.38–1.46) 0.391 0.92 (0.45–1.88) 0.817
Re-transplantation 0.21 (0.03–1.51) 0.121 0.18 (0.03–1.33) 0.094
Desensitization 1.50 (0.89–2.53) 0.126 1.55 (0.89–2.71) 0.123
Abbreviations: BMI, body mass index; CI, confidence interval; HLA, human leukocyte antigen; HR, hazards ratio; TAC, tacrolimus.
https://doi.org/10.1371/journal.pone.0235418.t005
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requirement of TAC, and TAC trough levels [28–30]. CYP3A5 is the major enzyme responsi-
ble for the metabolisms TAC. The CYP3A5 genetic polymorphisms can affect the pharmacoki-
netics of TAC and contribute to the interindividual variability of TAC trough levels. Previous
studies reported that CYP3A5 genotype is associated with dose-adjusted level of TAC and
complications among Korean KTRs [30, 31]. Although no information on CYP3A5 gene poly-
morphism has been obtained from the current study, further studies regarding the genotype-
guided TAC dosage control will ultimately be necessary to achieve individual optimized TAC
Fig 3. Development of de novo DSAs after 1 year post-transplant according to TAC trough levels. No significant difference in de novo DSA development between the
HL-TAC and LL-TAC groups was observed in the Kaplan-Meier plot. Abbreviations: DSA, donor-specific anti-HLA antibody; LL, low-level; HL, high-level; TAC,
tacrolimus.
https://doi.org/10.1371/journal.pone.0235418.g003
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trough levels and achieve the optimal transplant outcomes. Third, there are no data on the
presence of proteinuria over time, which may have yielded more useful information for the
evaluation of recurrent or newly occurring glomerulonephritis after kidney transplantation
which are a frequent cause of allograft loss at 10 years [32]. Despite these limitations, this study
could provide Asian clinicians with some guidance about TAC trough levels after 1 year post-
transplant because it included an Asian population, in contrast to prior studies that included
Caucasian, African American, and Hispanic populations. Furthermore, the results of this
study are clinically significant, demonstrating that stable KTRs who have never experienced
renal or cardiovascular outcomes make up the largest number of patients in clinical practice.
In addition, the mean follow-up duration was considerably long.
In conclusion, TAC trough levels after 1 year post-transplant were not directly associated
with long-term outcomes in stable Korean KTRs who did not experience renal or cardiovascu-
lar outcomes. Therefore, in Asian KTRs who have not experienced any outcomes in the first
year, TAC trough levels higher than approximately 6 ng/mL might not be required after a year
of kidney transplantation.
Fig 4. eGFRs at 2, 3, 4, and 5 years post-transplant. There were no significant differences in eGFRs at 2 years (67.0 ± 18.1 vs. 65.5 ± 18.8 mL/min/1.73 m2, P = 0.648), 3
years (67.8 ± 19.4 vs. 67.1 ± 20.2 mL/min/1.73 m2, P = 0.662), 4 years (66.9 ± 21.4 vs. 65.2 ± 20.8 mL/min/1.73 m2, P = 0.417), and 5 years (68.3 ± 21.3 vs. 64.9 ± 24.4 mL/
min/1.73 m2, P = 0.273) between the HL-TAC and LL-TAC groups. Abbreviations: eGFR, estimated glomerular filtration rate; LL, low-level; HL, high-level; TAC,
tacrolimus.
https://doi.org/10.1371/journal.pone.0235418.g004
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